Briumvi™ (ublituximab-xiiy) – New drug approval
December 28, 2022 - TG Therapeutics announced the FDA approval of Briumvi (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Top